Company news
Bluenergies Ltd. (TSXV:BLU) news
Bluenergies Ltd. news releases on 6ix. Latest, Sep 18, 2017: BELLUS Health's Blu-5937 Significantly Reduces Cough Without Taste Disturbance in Two Preclinical…
Press releases — page 2
BELLUS Health's Blu-5937 Significantly Reduces Cough Without Taste Disturbance in Two Preclinical Models
September 18, 2017
BELLUS Health to host webcast on chronic cough and treatment approach on September 20, 2017
September 6, 2017
BELLUS Health Reports Financial and Operating Results for the Second Quarter Ended June 30, 2017
August 9, 2017
Daily Coverage on Healthcare Stocks: BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics
July 12, 2017
BELLUS Health announces closing of the sale of its equity interest in FB Health for total consideration up to CA$2.5M
July 3, 2017
BELLUS Health announces sale of its equity interest in FB Health for total consideration up to CA$2.5M
June 19, 2017
Research Reports Initiated on Healthcare Stocks BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics
June 2, 2017
BELLUS Health Reports Financial and Operating Results for the First Quarter Ended March 31, 2017
May 9, 2017
BELLUS Health to present at Bloom Burton & Co. Healthcare Investor Conference
April 27, 2017
BELLUS Health Announces Grant of New U.S. Patent Covering Lead Compound for Chronic Cough
April 24, 2017
Research Reports Initiated on Healthcare Stocks BELLUS Health, Resverlogix, Helius Medical Technologies, and IntelliPharmaCeutics International
March 29, 2017
BELLUS Health Announces the Sale of Subsidiary Thallion Pharmaceuticals to Taro Pharmaceuticals
March 16, 2017
Bellus Health Reports Financial and Operating Results for the Year Ended December 31, 2016
February 28, 2017
BELLUS Health and The NEOMED Institute Announce an Exclusive Worldwide License Agreement for the Development of a Treatment for Chronic Cough
February 28, 2017
Research Reports Initiated on Healthcare Stocks Oncolytics Biotech, BELLUS Health, Emerald Health Therapeutics, and OrganiGram Holdings
February 27, 2017
Bellus Health Announces Payment to Thallion CVR Holders
February 17, 2017
BELLUS Health provides update on pipeline
December 21, 2016
BELLUS Health reports financial and operating results for the third quarter ended September 30, 2016
November 10, 2016
BELLUS Health Provides Update on Project Pipeline and Reports Financial and Operating Results for the Second Quarter Ended June 30, 2016
August 9, 2016
BELLUS Health announces top-line Phase 3 results of KIACTA(TM) for the treatment of AA amyloidosis
June 20, 2016
BELLUS Health and Pharmascience announce scheduled conversion of Pharmascience's interest in BHI Limited Partnership
June 2, 2016
BELLUS Health reports financial and operating results for the first quarter ended March 31, 2016
May 12, 2016
Bellus Health Reports Financial and Operating Results for the Year Ended December 31, 2015
February 24, 2016
Auven Therapeutics and Bellus Health Announce Completion of Pivotal Phase 3 Confirmatory Trial of KIACTA(TM) for the Treatment of Orphan Disease AA Amyloidosis
January 21, 2016
Bellus Health announces scheduled settlement of convertible notes
January 1, 2016
BELLUS Health reports financial and operating results for the third quarter ended September 30, 2015
November 12, 2015
BELLUS Health announces oral and poster presentations highlighting Shigamab(TM) for the treatment of hemolytic uremic syndrome
September 9, 2015
BELLUS Health narrows timelines for the Phase III study for KIACTA™ and reports financial and operating results for the second quarter ended June 30, 2015
August 12, 2015
Bellus Health Reports Financial and Operating Results for the First Quarter Ended March 31, 2015
May 12, 2015
BELLUS Health reports results for the year ended December 31, 2014
February 25, 2015
BELLUS Health announces sale of ABCP Notes and settlement of credit facilities
November 26, 2014
Bellus Health Reports Results for Third Quarter Ended September 30, 2014
November 5, 2014
BELLUS Health Reports Results for Second Quarter Ended June 30, 2014
August 13, 2014
Auven Therapeutics and BELLUS Health announce completion of enrollment in the Phase III Confirmatory Study of KIACTA(TM) for the treatment of AA amyloidosis
May 27, 2014
BELLUS Health reports results for first quarter ended March 31, 2014, and provides update on rare disease pipeline
May 7, 2014
Auven Therapeutics and BELLUS Health Announce Engagement of Financial Advisor to Explore Sale of KIACTA(TM), an Experimental Drug in Phase III Development for the Treatment Of AA Amyloidosis
May 7, 2014
Auven Therapeutics and BELLUS Health Announce Licence Agreement with Mount Sinai for KIACTA(TM) in Sarcoidosis
May 2, 2014
BELLUS Health reports results for year ended December 31, 2013
February 26, 2014
BELLUS Health provides update on KIACTA(TM) Phase III orphan drug study
January 9, 2014
BELLUS Health reports results for third quarter ended September 30, 2013
November 5, 2013
BELLUS Health and AmorChem Announce a Partnership to Develop Drug Candidates for AL Amyloidosis
October 28, 2013
BELLUS Health Out-Licenses VIVIMIND, BLU8499 and Its Analogs
October 23, 2013
TSX Venture Exchange Daily Bulletins
August 20, 2013
BELLUS Health announces closing of the acquisition of Thallion Pharmaceuticals
August 15, 2013
BELLUS Health reports results for second quarter ended June 30, 2013
August 7, 2013
KIACTA(TM) Granted Orphan Drug Status in Japan
July 23, 2013
BELLUS Health to acquire Thallion Pharmaceuticals
June 18, 2013
BELLUS Health Reports Results for First Quarter Ended March 31, 2013, and Provides Update on KIACTA(TM) Phase III Confirmatory Study
May 15, 2013
BELLUS Health Reports Results for Year Ended December 31, 2012
February 27, 2013
BELLUS Health Reports Results for Third Quarter Ended September 30, 2012, and Provides an Update on KIACTA(TM) Phase III Confirmatory Study
November 8, 2012